Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2016 |
| End Date: | April 2018 |
| Contact: | Joanna Katzman, MD |
| Email: | JKatzman@salud.unm.edu |
| Phone: | 505-272-3342 |
The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal
Precaution" manner to patients with opioid substance use disorder. The objectives are to
decrease the number of fatal and nonfatal overdose deaths, to examine and understand the
risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional
opioid overdose risk utilizing an evidence-based screening questionnaire.
Precaution" manner to patients with opioid substance use disorder. The objectives are to
decrease the number of fatal and nonfatal overdose deaths, to examine and understand the
risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional
opioid overdose risk utilizing an evidence-based screening questionnaire.
Inclusion Criteria:
- All patients treated with methadone or buprenorphine as medication assisted treatment
at the UNM Addiction and Substance Abuse Program (UNM ASAP) aged 18 or older
Exclusion Criteria:
- Subjects who are allergic to naloxone and its inactive ingredients. Inactive
ingredients include buffering agents.
- Subjects younger than 18.
- Subjects not being treated at UNM ASAP.
We found this trial at
1
site
Albuquerque, New Mexico 87106
Phone: 505-994-7999
Click here to add this to my saved trials
